BIRC5 and glioblastoma: Given the lack of natural GBM selectivity of adenoviral receptors, we highlighted the need for additional selectivity and demonstrated that tumour-specific promoters can enhance the specificity of GBM cells, where the survivin promoter appears to be particularly well suited.